The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

[21] This was a smaller study that enrolled 74 patients 65 years and older with NYHA class II or III heart failure (defined by the Framingham criteria) and an ejection fraction ≥40%. Background ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...